The Peptide Question

A compound you cannot buy at a pharmacy, tested mostly in animals, is being sold as the answer to injuries that a well-run strength program already addresses. The interesting question isn't whether BPC-157 works. It's why the appetite for it is so large while the evidence stays so small.

The Deep Cut: What We Actually Know About Peptides

The word "peptides" has quietly become one of the most confident terms in recovery marketing, and one of the least precise. As a new discussion with physician Jordan Feigenbaum lays out, people use it to refer to a heterogeneous group of peptide medications and investigational compounds, lumped together as if they shared a single track record [2]. They don't. BPC-157 has attracted particular attention, promoted for injury recovery, tissue repair, performance and longevity — four different promises stacked onto one molecule [2].

Here is the part worth sitting with. The case for these compounds leans heavily on three kinds of evidence: animal studies, plausible biological mechanisms, and personal anecdotes [2]. Each of those is a legitimate starting point for research. None of them, alone or together, tells you what a compound does in a healthy adult human over time. A mechanism explains how something could work; it does not confirm that it does, or that the benefit outweighs the risk. The episode's framing is explicitly about how to interpret that gap — how to read animal data and anecdote without either dismissing them or treating them as proof [2]. It also flags that recent regulatory discussions bear directly on these compounds' medical status and availability, which is a polite way of saying their legal footing is unsettled [2].

This is where a second, sharper source becomes useful. Exercise scientist Nick Tiller has described how wellness and optimisation culture increasingly presents itself as "science-based" without the substance to match [3]. Citing studies, using technical language, or holding scientific credentials does not guarantee the underlying evidence is being represented accurately [3]. Tiller draws a distinction that applies almost perfectly to the peptide conversation: the difference between science communication and science commodification — evidence selectively packaged, overstated, and used to support claims that happen to be commercially attractive [3]. A peptide with a mechanism diagram and a citation list can look far more rigorous than a plain recommendation to train and sleep, even when the plain recommendation has vastly more human evidence behind it.

The contrast is stark when you look at what is well studied. For older adults with sarcopenia, a systematic review and meta-analysis examined strength training combined with whey protein and HMB supplementation — a deliberately narrow question, because earlier reviews muddied the picture by pooling many different supplements together [1]. That methodological care matters: it's the opposite of stacking claims onto one molecule. Resistance training itself has a growing evidence base in the prevention and management of chronic conditions, an area where it has historically received less attention than aerobic exercise despite its role in functional capacity, long-term mobility, and quality of life [4]. These are not glamorous interventions. They are the ones with the human data.

The honest summary is not "peptides are dangerous" or "peptides are useless." It's that the confidence surrounding them has run far ahead of what is currently known about their safety and their effects in humans [2]. Tiller's reminder is the useful one here: scepticism is distinct from cynicism [3]. Being unconvinced by BPC-157 is not the same as being closed to it. It's asking the compound to clear the bar that resistance training and studied supplementation have already cleared — and noticing that, for now, it hasn't.

Research Radar

1. A discussion with Jordan Feigenbaum examines the peptide medications increasingly promoted for injury recovery and longevity, and stresses that claims rest largely on animal studies, mechanisms and anecdotes rather than robust human trials [2]. Recent regulatory discussions also affect their medical status and availability [2].

1. A systematic review and meta-analysis narrowed its focus to strength training plus whey protein and HMB in older people with sarcopenia, correcting a common flaw in earlier reviews that combined many supplement types at once [1]. Cleaner questions produce more usable answers.

1. A narrative review argues that resistance training has been underweighted in chronic disease prevention relative to aerobic exercise, despite its importance for mobility and quality of life — and notes only about a quarter of adults meet muscle-strengthening guidelines [4].

One Thing to Try

Next time a product promises recovery, performance and longevity all at once, ask a single question: is the evidence from humans, or from animals, mechanisms and testimonials? [2] If you can't tell, that's your answer for today.

Worth Your Attention

• BPC-157 and Peptide Medications: What Do We Know? (Sigma Nutrition Radio) — A measured walk through what the evidence does and doesn't support [2].
• How Wellness & Optimisation Culture Can Commodify Science (Sigma Nutrition Radio) — Nick Tiller on the difference between science communication and selling science-flavoured products [3].
• Resistance Training in the Prevention of Chronic Conditions (Clinics and Practice) — The unglamorous intervention with real human data [4].
• Strength Training, Whey and HMB for Sarcopenia (Medicine) — A model of asking a narrow, answerable question [1].

The appeal of a peptide is the appeal of a shortcut past the slow, well-evidenced things. But the difference between science communication and science commodification is exactly the difference between evidence and packaging [3]. When a claim clears the bar that squats and protein have already cleared, it will be worth your attention. Until then, the boring answer is still the best one.